Across 22 Randomized Trials and Over 32,000 Patients, Semaglutide Nearly Doubled the Rate of Liver Disease Resolution. It Did Not Significantly Reverse the Scarring That Actually Determines Long-Term Outcomes.

Metabolic dysfunction-associated steatohepatitis, MASH, the inflammatory form of fatty liver disease previously known as NASH, has become one of the leading causes of chronic liver disease worldwide, tracking closely with the global rise in obesity and type 2 diabetes. Until recently, treatment options were genuinely limited, with resmetirom standing as the only approved pharmacotherapy and most patients unable to sustain the lifestyle and weight loss changes needed to meaningfully alter the disease course. Semaglutide, already reshaping the treatment landscape for diabetes, obesity, and cardiovascular risk, has generated significant interest as a potential MASH therapy. This meta-analysis from researchers at Tongji Hospital in Wuhan, China, is the most comprehensive synthesis to date of what semaglutide actually does and does not accomplish in liver disease, and it arrives at a moment when GLP-1 receptor agonists are being asked to do more than almost any drug class in recent memory.

Kan et al. systematically searched PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials evaluating semaglutide in patients with MASH, with an initial search through July 2024 and an updated search through August 2025. The meta-analysis followed PRISMA guidelines and was registered with PROSPERO. Trials were eligible if they enrolled adults with MASH or, recognizing the overlapping pathophysiology between metabolic conditions, enrolled patients with obesity or type 2 diabetes who had predefined liver injury biomarkers and metabolic parameters reported, with a minimum follow-up of 12 weeks and a placebo or active comparator group. The analysis examined histologic outcomes including MASH resolution and fibrosis regression, biomarker outcomes including liver enzymes and the Enhanced Liver Fibrosis score, and broader metabolic and mortality outcomes. Subgroup analyses stratified results by semaglutide dose and treatment duration to identify dose-response and duration-response relationships.

The meta-analysis included 22 randomized controlled trials encompassing 32,013 patients. Semaglutide significantly improved MASH resolution (RR 1.98, 95% CI 1.57 to 2.50), nearly doubling the likelihood of resolution compared to control. However, semaglutide did not yield a statistically significant improvement in fibrosis regression (RR 1.18, 95% CI 0.74 to 1.88). Semaglutide reduced liver steatosis (WMD −11.30%, 95% CI −18.70 to −3.91) and reduced the Enhanced Liver Fibrosis score (WMD −0.49, 95% CI −0.70 to −0.29). Significant reductions were also observed in liver enzymes, including alanine aminotransferase (WMD −5.55 U/L, 95% CI −9.21 to −1.89) and aspartate aminotransferase (WMD −3.85 U/L, 95% CI −7.67 to −0.03). Beyond liver-specific outcomes, semaglutide improved weight, glycemic control, and lipid parameters, and reduced all-cause mortality (RR 0.82, 95% CI 0.74 to 0.91) and cardiovascular risk (RR 0.83, 95% CI 0.75 to 0.92). Subgroup analyses found the greatest benefits in patients receiving higher doses, at least 2.0 mg weekly, and longer treatment durations, at least 12 months.

• —The analysis pooled trials originally designed for MASH alongside trials designed for obesity or type 2 diabetes that reported liver outcomes as secondary endpoints, introducing heterogeneity in study population and primary objective that could affect pooled estimates.
• —As the authors note, phase 3 trials specifically targeting MASH populations have been constrained by relatively small sample sizes, heterogeneous endpoints, and short study durations, meaning even this comprehensive synthesis is built on an underlying evidence base with real gaps.
• —The non-significant fibrosis regression finding has wide confidence intervals (0.74 to 1.88) that include the possibility of both no effect and a clinically meaningful effect, meaning this question is unresolved rather than definitively answered in the negative.
• —As a meta-analysis of RCTs with varying designs, dosing protocols, and population characteristics, the pooled estimates carry the inherent limitations of evidence synthesis, including potential publication bias and between-study heterogeneity.

Semaglutide reliably resolves the inflammatory component of MASH and produces meaningful improvements in liver enzymes, steatosis, and systemic metabolic and cardiovascular risk. It does not yet have convincing evidence of reversing the fibrosis that ultimately determines long-term liver outcomes. For patients with MASH and significant fibrosis, semaglutide is a genuinely useful tool, but it is one part of management, not a definitive cure, and the question of whether higher doses or longer treatment durations will eventually move the fibrosis needle remains open.